93 SEARCH RESULTS FOR: Policy Comments

NCCS Urges FDA to Finalize Graphic Health Warnings for Cigarette Packs and Advertisements

/in , , , , , /by

NCCS joined with public health and medical organizations in a comment letter to the U.S. Food and Drug Administration (FDA) regarding the proposed rule to establish health warnings for cigarette packages and advertisements. The comment letter outlines the overwhelming evidence that shows color graphic health warnings on cigarette packages and ads substantially increases and promotes greater public understanding of the dangers of smoking, […]

Read more

NCCS Concerned That Proposed ACA Rule Changes Could Raise Costs for Patients and Disrupt Treatment

/in , , , , , , , , , /by

NCCS and member organizations of the Cancer Leadership Council (CLC) submitted comments to the HHS in response to the agency’s Notice of Benefits and Payment Parameters for 2020. The Notice contains rules and provisions that will apply to the individual market (the Affordable Care Act marketplace), and small group health insurance markets. The letter states NCCS’ concerns about specific provisions that may threaten cancer patients’ access […]

Read more

NCCS and Cancer Leadership Council Highlight Potential Harm to Patients of Proposed Medicare Part D Changes

/in , , , , , , , , , /by

The Department of Health and Human Services (HHS) released recently a proposed rule to change Medicare Part D’s protected classes drug coverage. In response, NCCS joined with other patient and provider groups of the Cancer Leadership Council (CLC) to comment on how these proposed changes could impact patients. The proposed rule would give Medicare plans the option to limit coverage of drugs in six categories, including cancer drugs. […]

Read more

NCCS Letter to CMS Highlights Concerns About Proposed Medicare Part B Reforms

/in , , , , , , , , /by

On December 31st, NCCS submitted our final comment letter of the year to the Centers for Medicare and Medicaid Services regarding the advance notice of proposed rulemaking for the Medicare Part B drug program.
In the letter, we outlined concerns that this proposal could have on Medicare beneficiaries such as impacts on patient access to innovative therapies, as well as concerns regarding the enormous scope of the test. NCCS suggested […]

Read more

NCCS “Not Persuaded” Drug Pricing in DTC Ads Will Improve Doctor-Patient Communication

/in , , , , , , , , , /by

Earlier this year, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule that would require information about drug costs be included in direct-to-consumer (DTC) advertisements of prescription drugs and biological products. NCCS issued a statement regarding the proposal, saying, “While we understand […]

Read more

NCCS Joins with Cancer Leadership Council to Outline Concerns Regarding New “Step Therapy” Plan

/in , , , , , , , , /by

NCCS joined with other cancer organizations of the Cancer Leadership Council (CLC) in a letter to the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) regarding the new plan announced on August 7 that gives Medicare Advantage plans the option of applying step therapy for physician-administered and other Part B drugs. The letter outlines several concerns regarding the application of step therapy […]

Read more

NCCS Submits Recommendations to CMS Regarding Proposed Changes to Hospital Outpatient Prospective Payment System (OPPS)

/in , , , , , , , , /by

NCCS submitted a letter to the Centers for Medicare and Medicaid Services (CMS) on the proposed update to the hospital outpatient prospective payment system, known as OPPS, for calendar year 2019. In the letter, NCCS outlines support for a change in payment for clinical services that are provided at off-campus provider-based departments that will reduce cost-sharing for patients for clinic visits. Additionally, CMS included a “request for information” […]

Read more

NCCS Joins Cancer Leadership Council Recommendations to FDA Regarding the Biosimilar Action Plan

/in , , , , , , /by

NCCS joined with other organizations of the Cancer Leadership Council (CLC) in commenting on the FDA Biosimilar Action Plan (BAP). The comment letter commended the FDA for the development of a plan that balances both innovation and competition. The letter stated that these products provide significant benefits to cancer patients, but that they also come at a significant expense to patients and the health care system. […]

Read more

NCCS Raises Concerns Over Impact on Patients of Medicare Physician Fee Schedule Revisions

/in , , , , , , , , , /by

NCCS submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the Medicare physician fee schedule revisions proposed for calendar year 2019 and proposed revisions in the Quality Payment Program. In our comments, NCCS addressed proposed changes to evaluation and management services, which are provided in the office or outpatient setting and are a critical element of cancer care. CMS proposed creating a […]

Read more

NCCS Applauds Resolution to Block Short-Term Insurance Plans, Protect Those with Pre-Existing Conditions

/in , , , , , , , , , , /by

Washington, DC – NCCS applauds the efforts of Senator Tammy Baldwin (D-WI) and 30 of her colleagues to advance a resolution blocking the final rule permitting expansion of short-term plans. The final rule extending the availability of short-term plans will put more Americans at risk of purchasing junk insurance plans and will also undermine the individual insurance markets on which many people with cancer rely. “NCCS considers these new short-term plans a serious threat,” […]

Read more

Take Action

Stovall Award

The Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care is a unique opportunity for patients and survivors to recognize pioneers who are transforming the cancer care system.

Join CPAT

The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.

Share Your Story

NCCS represents the millions of Americans who share a common experience – the survivorship experience – living with, through and beyond a cancer diagnosis.

STAY CONNECTED

Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action

National Coalition for Cancer Survivorship
8455 Colesville Road  |  Suite 930  |  Silver Spring, MD 20910
877-NCCS-YES  |  info@canceradvocacy.org
Privacy Policy  |  Terms and Conditions

Copyright © 1995-2021 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.